Coty Inc. Cl A (0I4A)
London Exchange · UK · prices in USD · close of 22 Oct 2026
Key indicators
| Last close | USD 3.173 |
|---|---|
| 52-week range | 1.820 – 4.208 |
| Return, 1 month / 3 months | +22.9% / +17.5% |
| Return, 1 year / 3 years | −23.9% / −66.9% |
| Trend | Uptrend |
| RSI (14) | 65 |
| Volatility (1 year) | 52.7% |
| Worst drawdown (1 year) | -55.0% |
| Average daily value traded | 0.03M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Coty Inc. is a beauty company that makes and markets fragrances, colour cosmetics and skincare products. Its portfolio mixes owned brands with licensed fragrance and beauty names tied to fashion and celebrity labels. The company supplies mass-market retailers, drugstores, department stores and travel-retail outlets, reaching consumers across many countries. Coty is based in New York, with substantial operations in Europe and other regions, and it develops, produces and distributes its products through those retail channels.
Coty Inc. Cl A trades under the code 0I4A on the London Exchange in UK, with its price quoted in US dollars (USD). Our dividend records, which start in 2019, show payments in 2 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Coty Inc. Cl A (0I4A) trades on the London Exchange in UK. It last closed at USD 3.173 on 22 October 2026.
Its price-based Market X-Ray is 46 out of 100 (a weak price profile), ranking 2,304 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 23.9% and over the last three months it rose 17.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 71 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 26.1% | ||
| From 52-week high | -23.9% | ||
| Momentum | 63 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 17.5% | ||
| 6-month return | 36.2% | ||
| 12-month return, skipping the last month | -38.1% | ||
| Stability (higher is calmer) | 20 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 52.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -55.0% | ||
| Liquidity | 19 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.03M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −0.2% |
|---|---|
| 1 month | +22.9% |
| 3 months | +17.5% |
| 6 months | +36.2% |
| 1 year | −23.9% |
| 3 years | −66.9% |
| 5 years | −60.6% |
Signals
| 50-day / 200-day average | 2.790 / 2.517 |
|---|---|
| Golden / death cross (60 days) | Golden, 34 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.120 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Feb 2020 | USD 0.1250 |
| 15 Nov 2019 | USD 0.1250 |
| 6 Sep 2019 | USD 0.1250 |
| 5 Jun 2019 | USD 0.1250 |
| 27 Feb 2019 | USD 0.1250 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.